SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind randomized phase 3 trial compared once-weekly tirzepatide at three doses with placebo as monotherapy in adults with type 2 diabetes.
- Who / model studied
- Adults with type 2 diabetes inadequately controlled by diet and exercise, who had not used injectable diabetes therapy, were studied.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- All tirzepatide doses improved HbA1c, fasting glucose, body weight, and target attainment versus placebo. Gastrointestinal events were the most frequent adverse events.
- Limitations & context
- Treatment discontinuations and early study discontinuations occurred during the trial.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)01324-6